Total and Regional Bone Mineral Content in Women Treated with GnRH Agonists

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 1993 May 1

PMID 8504372

Citations 6

Authors

H Rico

F Arnanz

M Revilla

S Perera

M Iritia

L F Villa

I Arribas

Affiliations

Soon will be listed here.

Abstract

Changes in bone mineral content induced by GnRH agonists were investigated by measuring total body bone mineral content (TBBM) and regional bone mineral content (BMC) (arms, legs, trunk, pelvis) and densities with dual energy X-ray absorptiometry in 25 premenopausal women before and after a 6-month treatment with gonadotropin-releasing hormone (GnRH) agonists. Biological markers of bone remodeling, estrogens, luteinizing hormone, and follicle-stimulating hormone were also measured. Weight and body mass index increased significantly after treatment (P < 0.05), and TBBM, corrected for weight (TBBM/W), decreased (P < 0.001). The changes in BMC that we observed ranged from +2.5% to -6.9%. The greatest decrease in regional BMC occurred in the trunk (4.4%, P < 0.001), with TBBM decreasing by 2.1% (P < 0.001). No significant changes were observed in the limbs. Tartrate-resistant acid phosphatase (TRAP) increased significantly after treatment (P < 0.001) and a significant negative correlation between TRAP and TBBM (P < 0.001) and between TRAP and estradiol (P < 0.001) were observed before treatment. The lack of changes observed in the BMC of the limbs indicate that GnRH agonists cause a preferential loss of BMC in trunk osseous structures, a situation similar to that of the first years of menopause.

Citing Articles

Crosstalk within a brain-breast-bone axis regulates mineral and skeletal metabolism during lactation.

Athonvarangkul D, Wysolmerski J Front Physiol. 2023; 14:1121579.

PMID: 36875035 PMC: 9979219. DOI: 10.3389/fphys.2023.1121579.

The evolutionary origins of maternal calcium and bone metabolism during lactation.

Wysolmerski J J Mammary Gland Biol Neoplasia. 2003; 7(3):267-76.

PMID: 12751891 DOI: 10.1023/a:1022800716196.

Bone mass in Parkinson's disease: a study with three methods.

Revilla M, de la Sierra G, Aguado F, Varela L, Jimenez-Jimenez F, Rico H Calcif Tissue Int. 1996; 58(5):311-5.

PMID: 8661963 DOI: 10.1007/BF02509377.

Bone mass measurements: reasons to be cautious.

Ott S BMJ. 1994; 308(6934):931-2.

PMID: 8173395 PMC: 2539801. DOI: 10.1136/bmj.308.6934.931.

Bone mass measurement for premenopausal women.

Lindsay R Osteoporos Int. 1994; 4 Suppl 1:39-41.

PMID: 8081057 DOI: 10.1007/BF01623434.

References

Goulding A, Fisher L . Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat. J Bone Miner Res. 1991; 6(11):1177-81. DOI: 10.1002/jbmr.5650061106. View

Rico H, Iritia M, Arribas I, Revilla M . [Biological profile of tartrate-resistant acid phosphatase as a marker of bone resorption]. Rev Esp Fisiol. 1990; 46(4):379-83. View

Hernandez E, Revilla M, Rico H . Total body bone mineral and pelvis bone mineral content as parameters of bone mass in men. A dual-energy X-ray absorptiometry study. Acta Anat (Basel). 1991; 142(3):227-30. DOI: 10.1159/000147193. View

Stepan J, Pospichal J, Schreiber V, Kanka J, MENSIK J, Presl J . The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone. Calcif Tissue Int. 1989; 45(5):273-80. DOI: 10.1007/BF02556018. View

Schiele F, Artur Y, Floch A, Siest G . Total, tartrate-resistant, and tartrate-inhibited acid phosphatases in serum: biological variations and reference limits. Clin Chem. 1988; 34(4):685-90. View

Fogelman I . Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril. 1992; 57(4):715-24. DOI: 10.1016/s0015-0282(16)54948-6. View

Harris S, Dallal G, Dawson-Hughes B . Influence of body weight on rates of change in bone density of the spine, hip, and radius in postmenopausal women. Calcif Tissue Int. 1992; 50(1):19-23. DOI: 10.1007/BF00297292. View

Wang J, Thornton J, Colt E, Pierson Jr R . Bone mineral density and mass by total-body dual-photon absorptiometry in normal white and Asian men. J Bone Miner Res. 1991; 6(10):1109-13. DOI: 10.1002/jbmr.5650061012. View

Johansen J, Riis B, Hassager C, Moen M, Jacobson J, Christiansen C . The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab. 1988; 67(4):701-6. DOI: 10.1210/jcem-67-4-701. View

10.

Rico H, Revilla M, Hernandez E, Villa L, Alvarez del Buergo M . Total and regional bone mineral content in relation to menopause. Maturitas. 1992; 15(3):233-40. DOI: 10.1016/0378-5122(92)90207-k. View

11.

Riis B, Christiansen C, Johansen J, Jacobson J . Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?. J Clin Endocrinol Metab. 1990; 70(4):920-4. DOI: 10.1210/jcem-70-4-920. View

12.

Rico H, Revilla M, Hernandez E, Villa L, Alvarez del Buergo M . Is pelvic bone mineral content assessed through dual energy X-ray absorptiometry an appropriate anatomical area for bone mass estimation in women?. Clin Rheumatol. 1992; 11(4):508-11. DOI: 10.1007/BF02283108. View

13.

Aaron J, Francis R, Peacock M, Makins N . Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop Relat Res. 1989; (243):294-305. View

14.

Kraenzlin M, Lau K, Liang L, Freeman T, Singer F, Stepan J . Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab. 1990; 71(2):442-51. DOI: 10.1210/jcem-71-2-442. View

15.

Genant H, Cann C, Ettinger B, GORDAN G . Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982; 97(5):699-705. DOI: 10.7326/0003-4819-97-5-699. View

16.

Delmas P . Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am. 1990; 19(1):1-18. View

17.

Stepan J, Musilova J, Pacovsky V . Bone demineralization, biochemical indices of bone remodeling, and estrogen replacement therapy in adults with Turner's syndrome. J Bone Miner Res. 1989; 4(2):193-8. DOI: 10.1002/jbmr.5650040210. View

18.

Saggese G, Bertelloni S, Baroncelli G, Pardi D, Cinquanta L . Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion. J Endocrinol Invest. 1991; 14(3):231-6. DOI: 10.1007/BF03346798. View

19.

Rico H, Revilla M, Hernandez E, Villa L, Lopez-Alonso A . Total and regional bone mineral content in normal premenopausal women. Clin Rheumatol. 1991; 10(4):423-5. DOI: 10.1007/BF02206664. View

20.

Matta W, Shaw R, Hesp R, Katz D . Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J (Clin Res Ed). 1987; 294(6586):1523-4. PMC: 1246674. DOI: 10.1136/bmj.294.6586.1523. View